Skip to main content
Jamie Chaft, MD, Oncology, New York, NY, Memorial Sloan-Kettering Cancer Center

JamieEChaftMD

Oncology New York, NY

Thoracic Cancer

Associate Attending Physician, Memorial Sloan-Kettering Cancer Center

Overview of Dr. Chaft

Dr. Jamie Chaft is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. She received her medical degree from NYU School of Medicine and has been in practice 11 years. Dr. Chaft accepts several types of health insurance, listed below. She is one of 389 doctors at Memorial Sloan-Kettering Cancer Center who specialize in Oncology.

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellowship, Hematology/Oncology, 2009 - 2012
  • New York Presbyterian Hospital - Cornell Campus
    New York Presbyterian Hospital - Cornell CampusResidency, Internal Medicine, 2006 - 2009
  • NYU School of Medicine
    NYU School of MedicineClass of 2006

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2020 - Present
  • NJ State Medical License
    NJ State Medical License 2017 - 2023
  • NY State Medical License
    NY State Medical License 2008 - 2023
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers  
    Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
  • Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)  
    Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
  • Pathologic Features of Response to Neoadjuvant Anti-PD-1 in Resected Non-Small Cell Lung Carcinoma: A Proposal for Quantitative Immune-Related Pathologic Response Crit...  
    J M Isbell, N Rekhtman, J D Wolchok, J E Chaft, Annals of Oncology
  • Join now to see all

Lectures

  • Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC. 
    2019 ASCO Annual Meeting - 6/1/2019
  • EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Clinical Challenges: Small Cell Lung Cancer
    Clinical Challenges: Small Cell Lung CancerNovember 15th, 2019
  • Cisplatin-Based Chemo: Still on Track in NSCLC
    Cisplatin-Based Chemo: Still on Track in NSCLCSeptember 7th, 2019
  • Lung Cancer: Immunotherapy Can Destroy Cancer Cells Completely
    Lung Cancer: Immunotherapy Can Destroy Cancer Cells CompletelyApril 17th, 2018

Hospital Affiliations

Insurance Accepted

  • GHI PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment